SCHEMBL17484615

SCHEMBL17484615

CCCCOc1ccc(OC(F)(F)F)cc1I

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.42
PPARD Q03181 2/20 0.42
FFAR1 O14842 2/20 0.41
FFAR4 Q5NUL3 2/20 0.41
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
F2 P00734 1/20 0.40
PLAU P00749 1/20 0.40
ST14 Q9Y5Y6 1/20 0.40
NR1I2 O75469 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
XDH P47989 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
PPARG P37231 1/20 0.38
GRM7 Q14831 1/20 0.37
ESR1 P03372 1/20 0.37
GPR3 P46089 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24313612 0.87 L3MBTL1 (0.47) L3MBTL1GRM7GPR3
SCHEMBL6199816 0.86 FFAR4 (0.39) PPARAPPARDFFAR1FFAR4F2
SCHEMBL13545909 0.81 PPARA (0.59) PPARAPPARDFFAR1FFAR4PPARG
SCHEMBL14850370 0.80 PPARA (0.44) PPARAPPARDFFAR1FFAR4THRA
SCHEMBL14028966 0.79 PTGDR2 (0.51) PPARAPPARDTHRATHRBL3MBTL1
SCHEMBL3342089 0.79 F2 (0.52) THRATHRBF2PLAUST14
SCHEMBL13205115 0.79 F2 (0.52) THRATHRBF2PLAUST14
SCHEMBL28819979 0.79 F2 (0.52) THRATHRBF2PLAUST14
SCHEMBL6417045 0.78 GPR3 (0.42) GRM7GPR3
SCHEMBL17354117 0.77 PPARA (0.41) PPARAPPARDFFAR1FFAR4THRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9505718-B2 3-piperidone compounds and their use as neurokinin-1 (NK1) receptor antagonists NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-11-29 US disclosed
US-20160031817-A1 3-PIPERIDONE COMPOUNDS AND THEIR USE AS NEUROKININ-1 (NK1) RECEPTOR ANTAGONISTS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031817-A1 3-PIPERIDONE COMPOUNDS AND THEIR USE AS NEUROKININ-1 (NK1) RECEPTOR ANTAGONISTS TACR1, NPSR1, TACR2 PPARA 2358/4885PPARD 2617/4885FFAR1 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.